SCHEMBL14740993

SCHEMBL14740993

O=C(OCc1ccccc1)c1c(Cl)ccnc1Cl

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.63
L3MBTL1 Q9Y468 3/20 0.51
KMT2A Q03164 3/20 0.50
TDP1 Q9NUW8 3/20 0.50
SLC6A2 P23975 1/20 0.50
SLC6A3 Q01959 1/20 0.50
MEN1 O00255 1/20 0.48
LMNA P02545 2/20 0.48
ALDH1A1 P00352 4/20 0.47
CASP3 P42574 2/20 0.47
SENP8 Q96LD8 2/20 0.47
SENP7 Q9BQF6 2/20 0.47
SENP6 Q9GZR1 2/20 0.47
NPSR1 Q6W5P4 1/20 0.46
TSHR P16473 1/20 0.46
RAB9A P51151 1/20 0.46
EGLN1 Q9GZT9 1/20 0.44
P2RX7 Q99572 1/20 0.44
JMJD6 Q6NYC1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4288275 0.82 POLB (0.56) POLBL3MBTL1KMT2ATDP1SLC6A2
SCHEMBL10475552 0.79 POLB (0.72) POLBL3MBTL1KMT2ATDP1SLC6A2
SCHEMBL30666434 0.78 CA12 (0.47) L3MBTL1LMNAALDH1A1NPSR1TSHR
SCHEMBL3579374 0.78 POLB (1.00) POLBL3MBTL1KMT2ATDP1MEN1
SCHEMBL28566933 0.78 POLB (0.65) POLBL3MBTL1KMT2ATDP1SLC6A2
SCHEMBL27267807 0.77 POLB (0.53) POLBL3MBTL1KMT2ATDP1SLC6A2
SCHEMBL4126151 0.77 POLB (0.50) POLBL3MBTL1KMT2AMEN1LMNA
SCHEMBL14741149 0.76 POLB (0.52) POLBL3MBTL1KMT2ATDP1SLC6A2
SCHEMBL6832244 0.76 TDP1 (0.59) POLBL3MBTL1KMT2ATDP1SLC6A2
SCHEMBL27032971 0.76 POLB (0.55) POLBKMT2ATDP1SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
WO-2016025933-A2 SUBSTITUTED POLYCYCLIC ANTIBACTERIAL COMPOUNDS PTC THERAPEUTICS, INC. (US) 2016-02-18 WO disclosed
WO-2016025932-A1 SUBSTITUTED POLYCYCLIC ANTIBACTERIAL COMPOUNDS PTC THERAPEUTICS, INC. (US) 2016-02-18 WO disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
CN-103889224-A ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS INC 2014-06-25 CN disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP POLB 84/4885L3MBTL1 321/4885KMT2A 4450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.